These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 34615727)

  • 1. Novel therapeutic targets for cholestatic and fatty liver disease.
    Trauner M; Fuchs CD
    Gut; 2022 Jan; 71(1):194-209. PubMed ID: 34615727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.
    Fuchs CD; Traussnigg SA; Trauner M
    Semin Liver Dis; 2016 Feb; 36(1):69-86. PubMed ID: 26870934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.
    Radun R; Trauner M
    Semin Liver Dis; 2021 Nov; 41(4):461-475. PubMed ID: 34289507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury.
    Petrescu AD; DeMorrow S
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR).
    Zhou S; You H; Qiu S; Yu D; Bai Y; He J; Cao H; Che Q; Guo J; Su Z
    Biomed Pharmacother; 2022 Oct; 154():113577. PubMed ID: 35988420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.
    Sun L; Cai J; Gonzalez FJ
    Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):335-347. PubMed ID: 33568795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease.
    Yang Z; Danzeng A; Liu Q; Zeng C; Xu L; Mo J; Pingcuo C; Wang X; Wang C; Zhang B; Zhang B
    Int J Biol Sci; 2024; 20(1):113-126. PubMed ID: 38164174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesoid X receptor modulators (2011 - 2014): a patent review.
    Sepe V; Distrutti E; Fiorucci S; Zampella A
    Expert Opin Ther Pat; 2015; 25(8):885-96. PubMed ID: 26183029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear receptors and nonalcoholic fatty liver disease.
    Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
    Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleiotropic functions of bile acids mediated by the farnesoid X receptor.
    Stanimirov B; Stankov K; Mikov M
    Acta Gastroenterol Belg; 2012 Dec; 75(4):389-98. PubMed ID: 23402081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bile acids as regulators of hepatic lipid and glucose metabolism.
    Trauner M; Claudel T; Fickert P; Moustafa T; Wagner M
    Dig Dis; 2010; 28(1):220-4. PubMed ID: 20460915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease.
    Wang J; Yang N; Xu Y
    Am J Chin Med; 2024; 52(2):291-314. PubMed ID: 38480498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
    Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
    JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting nuclear bile acid receptors for liver disease.
    Trauner M; Baghdasaryan A; Claudel T; Fickert P; Halilbasic E; Moustafa T; Zollner G
    Dig Dis; 2011; 29(1):98-102. PubMed ID: 21691114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic concepts in bile acid transport and signaling for management of cholestasis.
    Trauner M; Fuchs CD; Halilbasic E; Paumgartner G
    Hepatology; 2017 Apr; 65(4):1393-1404. PubMed ID: 27997980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesoid X receptor modulators 2014-present: a patent review.
    Sepe V; Distrutti E; Fiorucci S; Zampella A
    Expert Opin Ther Pat; 2018 May; 28(5):351-364. PubMed ID: 29649907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Environmental Chemical Contribution to the Modulation of Bile Acid Homeostasis and Farnesoid X Receptor Signaling.
    Taylor RE; Bhattacharya A; Guo GL
    Drug Metab Dispos; 2022 Apr; 50(4):456-467. PubMed ID: 34759011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis.
    Liu X; Wang J; Li M; Qiu J; Li X; Qi L; Liu J; Liu P; Xie G; Wang X
    J Gastroenterol Hepatol; 2023 Aug; 38(8):1438-1446. PubMed ID: 37415275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.